Guardant Health Inc   (GH)
Other Ticker:  
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
Price: $19.4200 $-2.85 -12.797%
Day's High: $22.02 Week Perf: -13.38 %
Day's Low: $ 19.11 30 Day Perf: -13.84 %
Volume (M): 5,346 52 Wk High: $ 41.06
Volume (M$): $ 103,819 52 Wk Avg: $28.74
Open: $21.00 52 Wk Low: $19.11

 Market Capitalization (Millions $) 2,175
 Shares Outstanding (Millions) 112
 Employees 1,100
 Revenues (TTM) (Millions $) 564
 Net Income (TTM) (Millions $) -479
 Cash Flow (TTM) (Millions $) 992
 Capital Exp. (TTM) (Millions $) 20

Guardant Health Inc
Guardant Health Inc. is a leading precision oncology company that aims to transform cancer care through comprehensive genomic sequencing solutions. The company is based in Redwood City, California, and was founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz.

Guardant Health's core technology is called Guardant360, a non-invasive liquid biopsy test that uses genomic sequencing to analyze a patient's cancer. This test allows oncologists to identify mutations and alterations in a patient's cancer DNA, which can help guide treatment decisions. In addition, Guardant Health has developed a range of other liquid biopsy tests, including GuardantOMNI, GuardantINFORM, and GuardantHEALTHY, which can detect cancer early, monitor disease progression, and identify potential relapse.

Guardant Health has also developed proprietary bioinformatics algorithms and machine learning techniques to interpret the large amounts of genomic data generated by these tests. These algorithms are used to predict a patient's response to various treatment options and identify new targets for therapeutics.

Guardant Health has partnerships with several global pharmaceutical companies to develop companion diagnostic tests for their cancer therapies. In addition, the company has formed collaborations with leading cancer centers and research institutions to conduct clinical trials and advance the use of liquid biopsies in cancer care.

In 2018, Guardant Health went public on the NASDAQ stock exchange, and its shares are now listed under the symbol GH. The company has rapidly grown its revenue and customer base, and in 2020, it was named one of the fastest-growing companies in North America by Deloitte's Technology Fast 500.

Guardant Health's mission is to help improve outcomes for cancer patients through precision oncology. The company is dedicated to using the power of genomics and data science to revolutionize cancer care and ultimately, find a cure for this devastating disease.

   Company Address: 3100 Hanover Street Palo Alto 94304 CA
   Company Phone Number: 698-8887   Stock Exchange / Ticker: NASDAQ GH


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Guardant Health Inc

Guardant Health Inc Sees Revenue Surge but Profitability Remains Elusive

As an analyst for the , I have been closely following the financial results of Guardant Health Inc (GH) for the fiscal period ending December 31, 2023. The company announced a significant 22.195% surge in revenue to $155.05 million compared to the previous year, outperforming many of its competitors in the Medical Laboratories sector. However, this growth in revenue was accompanied by an increased shortfall per share at $-1.39, which is a cause for concern among investors.
In the fourth quarter of 2023, GH experienced a noteworthy revenue increase of 8.407% compared to the prior quarter, although the shortfall per share also increased to $-0.73. Additionally, the company reported a net deficit of $-187.043 million for the fiscal period, which is a significant increase from the previous year.

Guardant Health Inc

Guardant Health Inc Experiences a Revenue Shortfall of $-0.73 per Share in Fiscal Quarter Ending September 30, 2023

Guardant Health Inc, a leading medical laboratories company, has witnessed a remarkable increase in its share price over the past five trading days and in the last 12 months. Additionally, the company recently announced impressive revenue growth in the third quarter of 2023, outperforming its sector peers. This article delves into the financial results and explores the potential impact on Guardant Health Inc's future prospects.
1. Revenue Growth and Loss per Share in Q3 2023:
Guardant Health Inc experienced a surge in revenue by 21.827% to $143.03 million during July to September 2023 compared to the same period the previous year. Despite this revenue growth, the company reported a loss of $-0.73 per share. While the loss per share is a concern, the strong revenue increase suggests that Guardant Health Inc is gaining traction in the market.

Guardant Health Inc

Guardant Health Inc. Sails Through Fiscal Uncertainty with Stellar Revenue Surge!

Guardant Health Inc, a leading precision oncology company, has shown remarkable resilience in the highly competitive stock market during the April to June 30, 2023 fiscal time-frame. Despite a somewhat rocky performance in the past, the company has managed to turn the tide in its favor by improving its financials and making significant strides towards profitability. Let's delve deeper into the interesting facts that have emerged during this period.
Earnings and Losses Per Share:
One of the most significant developments for Guardant Health Inc is the reduction in loss per share from $-2.25 to $-0.67 when comparing the same quarter from the previous year. This indicates a substantial improvement, suggesting that the company is moving closer to achieving profitability. Furthermore, there has been a positive sequential growth in earnings per share, from $-1.30 in the preceding quarter to an undisclosed amount in the current quarter.

Guardant Health Inc

Guardant Health Inc Shines with Impressive Revenue Surge in Q1 2023 Earnings Season

Guardant Health Inc: A Strong Future Despite Diminishing Returns
Guardant Health Inc, a leading Medical Laboratories company, reported its Q1 2023 earnings on Tuesday, and while the report showed a decrease in earnings per share, the company's remarkable revenue surge up to $128.71 million provided a silver lining.
The decline in earnings per share to $-1.30 from $-1.35 per share in the prior reporting period is a moderate setback for any company. Still, Guardant Health remained resilient in its ability to generate income as a result of its 33.939% increase in revenue from the same period last year, which is a remarkable achievement.


Guardant Health Inc's Segments
• View Complete Report
  Company Estimates  
  Revenue Outlook
Guardant Health Inc does not provide revenue guidance.

Earnings Outlook
Guardant Health Inc does not provide earnings estimates.

Geographic Revenue Dispersion


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com